Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Belur Patel

Urology Victoria, TX Medical Doctor

NPI 1891756680 CMS profile 312911

2701 Hospital Dr, Victoria, TX 77901

Open in the dashboard

General payments

$5,455

82 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$34,321 paid to institutions, not to them · program years 2021–2022

Through program year 2025, Belur Patel of Victoria, TX is reported in the CMS Open Payments database as having received $5,455 across 82 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $34,321 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 67th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $984 16
2024 General $1,424 25
2023 General $605 11
2022 General $860 9
2021 General $492 5
2020 General $213 3
2019 General $877 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Belur Patel
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Belur Patel were reported at $984. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Belur Patel Urology median Middle half National median
2019 $877 $480 $147–$1,201 $163
2020 $213 $246 $87–$645 $114
2021 $492 $358 $111–$1,000 $132
2022 $860 $476 $143–$1,263 $149
2023 $605 $560 $168–$1,461 $160
2024 $1,424 $563 $170–$1,464 $164
2025 $984 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. PROCEPT BioRobotics Corporation $1,473 12 payments
  2. Boston Scientific Corporation $435 7 payments
  3. Astellas Pharma US Inc $404 15 payments
  4. Calyxo, Inc. $362 2 payments
  5. Janssen Biotech, Inc. $312 5 payments
  6. Medtronic, Inc. $302 4 payments
  7. Olympus America Inc. $271 3 payments
  8. Metuchen Pharmaceuticals $259 1 payment
  9. Cook Medical LLC $211 4 payments
  10. Coloplast Corp $188 3 payments
  11. Other $1,237 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,638 77 payments
  2. Travel and Lodging $552 2 payments
  3. Education $264 3 payments
Products named General payments · program years 2019–2025
  1. AQUABEAM SYSTEM $927 7 payments
  2. AQUABEAM ROBOTIC SYSTEM $547 5 payments
  3. CVAC ASPIRATION SYSTEM $362 2 payments
  4. ERLEADA $312 5 payments
  5. XTANDI $262 10 payments
  6. Stendra $259 1 payment
  7. INTERSTIM $213 2 payments
  8. GENERAL KIDNEY STONE DISEASE $199 3 payments
  9. GEMTESA $173 4 payments
  10. iTIND System $171 2 payments
  11. Other $1,781 41 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

662

Median for Urology: 1,053

Drug cost

$4,304

Median for Urology: $101,464

Branded share of claims

16.8%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tamsulosin Hcl Generic 286 $2,134
Finasteride Generic 53 $621
Trospium Chloride Generic 23 $490
Oxybutynin Chloride Generic 21 $276
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 82 $195
Levofloxacin Generic 93 $188
Tramadol Hcl Generic 75 $170
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 18 $130
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 11 $100

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$123,348

Of which drugs: $8,572

Medicare patients

360

Average age 76

Services billed

1,438

53 women, 307 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 43%
Ischemic heart disease 37%
Cancer 31%
Chronic kidney disease 30%
Atrial fibrillation 24%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, garamycin, gentamicin, up to 80 mg J1580 Office 20 20 $36

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ERLEADA
  • Janssen Biotech, Inc. $73
$73 — —
XTANDI
  • Astellas Pharma US Inc $52
$52 — —
XYOSTED
  • Antares Pharma, Inc. $45
$45 — —
MYRBETRIQ
  • Astellas Pharma US Inc $43
$43 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

82 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record